Recurrent Cervical Carcinoma Clinical Trial
Official title:
A Phase II Evaluation of Cetuximab (Erbitux®, C225, NSC# 714692) in the Treatment of Persistent or Recurrent Squamous or Non-Squamous Cell Carcinoma of the Cervix
Verified date | December 2014 |
Source | Gynecologic Oncology Group |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Food and Drug Administration |
Study type | Interventional |
This phase II trial is studying cetuximab to see how well it works in treating patients with persistent or recurrent cervical cancer. Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them.
Status | Completed |
Enrollment | 38 |
Est. completion date | |
Est. primary completion date | January 2012 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Inclusion criteria: - Patients must have persistent or recurrent squamous or non-squamous cell carcinoma of the cervix with documented disease progression (disease not amenable to curative therapy) - Histologic documentation of the original primary tumor is required via the pathology report - All patients must have measurable disease defined as at least one lesion that can be accurately measured in at least one dimension (longest dimension to be recorded) - Each lesion must be = 20 mm when measured by conventional techniques, including palpation, plain x-ray, CT scan, and MRI, OR = 10 mm when measured by spiral CT scan - Patients must have at least one target lesion to be used to assess response on this protocol - Tumors within a previously irradiated field will be designated as nontarget lesions unless progression is documented or a biopsy is obtained to confirm persistence at least 90 days following completion of radiation therapy - Patients must have had one prior systemic chemotherapeutic regimen for management of advanced, metastatic, or recurrent carcinoma of the cervix - Chemotherapy administered in conjunction with primary radiation as a radiosensitizer is not counted as a systemic chemotherapy regimen - Patients must not be eligible for a higher priority GOG protocol, if one exists - In general, this would refer to any active GOG phase III protocol for the same patient population - Exclusion criteria: - Patients with craniospinal metastases - Inclusion criteria: - Patients who have received one prior regimen must have a GOG performance status of 0, 1, or 2 or patients who have received two prior regimens must have a GOG performance status of 0 or 1 - Patients should be free of active infection requiring antibiotics - Platelet count = 100,000/µl - ANC = 1,500/µl - Creatinine = 1.5 x institutional upper limit normal (ULN) - Bilirubin = 1.5 x ULN - SGOT and alkaline phosphatase = 2.5 x ULN - Neuropathy (sensory and motor) = CTCAE v3.0 grade 1 - Calcium < 11.0 mg/dL - Patients of childbearing potential must have a negative serum pregnancy test within 7 days prior to initiating protocol therapy and be practicing an effective form of contraception during protocol therapy and for at least two months following completion of protocol therapy - Exclusion criteria: - Patients with a history of other invasive malignancies, with the exception of nonmelanoma skin cancer and other specific malignancies, are excluded if there is any evidence of other malignancy being present within the last five years - Patients are also excluded if their previous cancer treatment contraindicates this protocol therapy - Patients who have a significant history of cardiac disease (i.e., uncontrolled hypertension, unstable angina, uncontrolled congestive heart failure, or uncontrolled arrhythmias) within 6 months of registration - Patients who have an uncontrolled seizure disorder or active neurological disease - Patients known to be seropositive for HIV and active hepatitis, even if liver function studies are in the eligible range - Pregnant or nursing women or women of childbearing potential unless using effective contraception as determined by the investigator - Known hemorrhagic diathesis or active bleeding disorder - Inclusion criteria: - Recovery from effects of recent surgery, radiotherapy, or chemotherapy - Any hormonal therapy directed at the malignant tumor must be discontinued at least one week prior to registration (continuation of hormone replacement therapy is permitted) - Any other prior therapy directed at the malignant tumor, including immunologic agents, must be discontinued at least three weeks prior to registration - Patients are allowed to receive, but are not required to receive, one additional cytotoxic regimen for management of recurrent or persistent cervical disease according to the following definition: - Cytotoxic regimens include any agent that targets the genetic and/or mitotic apparatus of dividing cells, resulting in dose-limiting toxicity to the bone marrow and/or gastrointestinal mucosa - Patients must not have received any non-cytotoxic therapy for management of recurrent or persistent cervical disease - Patients must not be receiving any other investigational agent - Exclusion criteria: - Patients who have received prior therapy with cetuximab or any other anti-epidermal growth factor receptor antibody - Patients who have received any prior therapy with a tyrosine kinase inhibitor that targets the EGFR pathway - Patients who have received prior chimerized or murine monoclonal antibody therapy - Patients who have received prior radiotherapy to any portion of the abdominal cavity or pelvis other than for the treatment of cervical cancer within the last five years are excluded - Prior radiation for localized cancer of the breast, head and neck, or skin is permitted, provided that it was completed more than three years prior to registration and the patient remains free of recurrent or metastatic disease - Patients who have received prior chemotherapy for any abdominal or pelvic tumor other than for the treatment of cervical cancer within the last five years are excluded - Patients may have received prior adjuvant chemotherapy for localized breast cancer, provided that it was completed more than three years prior to registration and that the patient remains free of recurrent or metastatic disease - Patients who have undergone major surgery, excluding diagnostic biopsy, within 30 days (to allow for full recovery) prior to registration |
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | Abington Memorial Hospital | Abington | Pennsylvania |
United States | Akron General Medical Center | Akron | Ohio |
United States | AnMed Health Hospital | Anderson | South Carolina |
United States | Colorado Gynecologic Oncology Group | Aurora | Colorado |
United States | Island Gynecologic Oncology | Brightwaters | New York |
United States | University of North Carolina | Chapel Hill | North Carolina |
United States | Carolinas Medical Center | Charlotte | North Carolina |
United States | MetroHealth Medical Center | Cleveland | Ohio |
United States | Riverside Methodist Hospital | Columbus | Ohio |
United States | Decatur Memorial Hospital | Decatur | Illinois |
United States | M D Anderson Cancer Center | Houston | Texas |
United States | Saint Vincent Hospital and Health Services | Indianapolis | Indiana |
United States | Froedtert and the Medical College of Wisconsin | Milwaukee | Wisconsin |
United States | The Hospital of Central Connecticut | New Britain | Connecticut |
United States | Memorial Sloan-Kettering Cancer Center | New York | New York |
United States | University of Oklahoma Health Sciences Center | Oklahoma City | Oklahoma |
United States | Singing River Hospital | Pascagoula | Mississippi |
United States | Women and Infants Hospital | Providence | Rhode Island |
United States | CoxHealth South Hospital | Springfield | Missouri |
United States | Stony Brook University Medical Center | Stony Brook | New York |
United States | Cancer Care Associates-Midtown | Tulsa | Oklahoma |
United States | Tulsa Cancer Institute | Tulsa | Oklahoma |
Lead Sponsor | Collaborator |
---|---|
Gynecologic Oncology Group | National Cancer Institute (NCI) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Progression-free Survival Greater Than 6 Months | At 6 months | No | |
Primary | Objective Tumor Response Assessed by Response Evaluation Criteria in Solid Tumors (RECIST) | Response is measured according to Response Evaluation Criteria in Solid Tumors Criteria (RECIST v 1.0): Complete Response (CR) is disappearance of all target and non-target lesions and no evidence of new lesions documented by two disease assessments at least 4 weeks apart. Partial Response (PR) is at least a 30% decrease in the sum of longest dimensions (LD) of all target measurable lesions taking as reference the baseline sum of LD. Disease Progression is at least a 20% increase in the sum of LD of target lesions taking as references the smallest sum LD or the appearance of new lesions within 8 weeks of study entry. Stable Disease is any condition not meeting the above criteria. Indeterminate is defined as having no repeat tumor assessments following initiation of study therapy for reasons unrelated to symptoms or signs of disease. |
every other cycle for the first 6 months; then every 3 months x 2; then every 6 months | No |
Secondary | Duration of Progression-free Survival | From study entry until disease progression, death or date of last contact, up to 5 years | No | |
Secondary | Duration of Objective Response Rate | Up to 5 years | No | |
Secondary | Frequency and Severity of Adverse Effects as Assessed by Common Terminology Criteria for Adverse Events Version 3.0 | Up to 5 years | Yes | |
Secondary | Duration of Overall Survival | From study entry to death or the date of last contact, up to 5 years | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03968406 -
Talazoparib and Radiation Therapy in Treating Patients With Locally Recurrent Gynecologic Cancers
|
Phase 1 | |
Active, not recruiting |
NCT03508570 -
Nivolumab With or Without Ipilimumab in Treating Patients With Recurrent or High Grade Gynecologic Cancer With Metastatic Peritoneal Carcinomatosis
|
Phase 1 | |
Completed |
NCT00309959 -
ABI-007 in Treating Patients With Persistent or Recurrent Cervical Cancer
|
Phase 2 | |
Recruiting |
NCT04574635 -
Human Papilloma Virus (HPV) Circulating Tumor DNA (ctDNA) in Cervical Cancer
|
||
Recruiting |
NCT04635956 -
Camrelizumab Combined With Chemotherapy for Recurrent or Advanced Cervical Neuroendocrine Carcinomas
|
Phase 2 | |
Active, not recruiting |
NCT03439085 -
DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine INO-3112 and Durvalumab in Treating Patients With Recurrent or Metastatic Human Papillomavirus Associated Cancers
|
Phase 2 | |
Recruiting |
NCT03987555 -
Paclitaxel Therapeutic Drug Monitoring in Cancer Patients
|
||
Terminated |
NCT03345784 -
Testing AZD1775 inC Combination With Radiotherapy and Chemotherapy in Cervical, Upper Vaginal and Uterine Cancers
|
Phase 1 | |
Completed |
NCT01266460 -
Vaccine Therapy in Treating Patients With Persistent or Recurrent Cervical Cancer
|
Phase 2 | |
Completed |
NCT00064077 -
Comparison of Four Combination Chemotherapy Regimens Using Cisplatin in Treating Patients With Stage IVB, Recurrent, or Persistent Cancer of the Cervix
|
Phase 3 | |
Active, not recruiting |
NCT02257528 -
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
|
Phase 2 | |
Recruiting |
NCT05310383 -
Tislelizumab and Radiotherapy for Recurrent Cervical Cancer
|
Phase 2 | |
Recruiting |
NCT05310331 -
Donafenib for Recurrent Cervical Cancer
|
Phase 2 | |
Recruiting |
NCT05310305 -
PD-1 Antibody and Radiotherapy for Recurrent Cervical Cancer
|
||
Completed |
NCT01281852 -
Paclitaxel, Cisplatin, and Veliparib in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer
|
Phase 1 | |
Recruiting |
NCT05290935 -
Immunotherapy for Recurrent Cervical Cancer Refractory to Platinum-based Chemotherapy: Multi-Center Trial
|
Phase 2 | |
Recruiting |
NCT06238635 -
Dostarlimab and Cobolimab in Advanced Cervical Cancer
|
Phase 2 | |
Completed |
NCT02921269 -
Atezolizumab and Bevacizumab in Treating Patients With Recurrent, Persistent, or Metastatic Cervical Cancer
|
Phase 2 | |
Recruiting |
NCT06157151 -
PRGN-2009 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer
|
Phase 2 | |
Completed |
NCT00041093 -
Docetaxel in Treating Patients With Persistent or Recurrent Cervical Cancer
|
Phase 2 |